Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
If you are wondering whether Arcutis Biotherapeutics at about US$26.20 is offering good value or carrying extra risk, you are not alone. The stock has returned 1.4% over the last 7 days, while the 30 day and year to date returns are both around a 10% decline, set against an 89.2% return over the past year and 58.2% over three years. Recent news flow around Arcutis Biotherapeutics has centered on its position in the pharmaceuticals and biotech space and ongoing interest in its dermatology focused pipeline and commercial execution. These updates help frame how investors are reacting to the stock after a period of strong longer term returns but mixed shorter term moves. On Simply Wall St's valuation checks, Arcutis Biotherapeutics scores a 3 out of 6 . This means some measures point to undervaluation while others are more neutral. Next, we will look at how different valuation methods line up before finishing with a more rounded way to think about value beyond the headline numbers.
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic DermatitisGlobeNewswire
- Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
ARQT
Earnings
- 10/28/25 - Beat
ARQT
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- ARQT's page on the SEC website